Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + Tislelizumab + Apatinib for Unresectable ICC
NCT05290116Phase 2Unknown
- Start
- Jul 2022
- Primary completion
- May 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, Rivoceranib in intrahepatic cholangiocarcinoma (ICC). Status: unknown.
02
Drugs
tislelizumabRivoceranib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05290116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05290116.